Latest Breaking News On - Zynerba pharmaceuticals - Page 1 : comparemela.com

HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME

/PRNewswire/ Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to.

United statesLuis sanayKumar budurExchange commissionZynerba pharmaceuticalsPrnewswire harmony biosciences holdings incDrug administrationParagon biosciencesUs food drug administrationBiosciences holdingsOrphan drug designationChief medical officerFull prescribing informationHarmony biosciencesPlymouth meetingPrivate securities litigation reform act

Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

WAKIX® Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively U.S. Food and Drug Administration Granted.

United statesUnited kingdomLuis sanayJeffreym daynoIdiopathic hypersomnia development program scheduled forParagon biosciencesEuropean medicines agencyDrug administrationEuropean unionZynerba pharmaceuticalsExchange commissionHarmony biosciences holdings incNet revenueFourth quarterFull yearRepresenting growth

Pridopidine Market Size and Share Across 7MM and Competitive

Pridopidine Market Size and Share Across 7MM and Competitive
openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.

Zynerba pharmaceuticalsFragilex syndrome pipeline insightFragilex syndromeKey players

HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2023 NET PRODUCT REVENUE INCREASES MORE THAN 30 PERCENT; PROVIDES 2024 NET PRODUCT REVENUE GUIDANCE

/PRNewswire/ Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported preliminary, unaudited fourth quarter and full year 2023 net product revenue.

United statesLuis sanayJeffreym daynoDrug administrationParagon biosciencesZynerba pharmaceuticalsExchange commissionPrnewswire harmony biosciences holdings incShare repurchase programPreliminary net revenueFourth quarterFull yearRepresenting growthProduct revenue projected betweenCommon stock repurchaseFourth quarter bringing

DelveInsight Business Research, LLP: In-Depth Market Analysis of Rare Genetic Disorders: Familial Chylomicronemia Syndrome (FCS), Netherton Syndrome, and Acromegaly

DelveInsight Business Research, LLP: In-Depth Market Analysis of Rare Genetic Disorders: Familial Chylomicronemia Syndrome (FCS), Netherton Syndrome, and Acromegaly
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesAvanti biosciencesDaiichi sankyoStefan klotterDaelis farmaVyant bioSixera pharmaReveragen biopharmaAnnovis bioShruti thakurLinearis circumflexaConfluence pharmaceuticalsArrowhead pharmaceuticals incNeuren pharmaceuticalsRare disease consulting servicesNeuronascent inc